32940 Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 

autoimmunity. Annu Rev Immunol. 

2008;26:57–79. 

2. WJ Leonard and R Spolski. 

Interleukin-21: A modulator of 

lymphoid proliferation, apoptosis and 

differentiation. Nat Rev Immunol. 2005 

Sep;5(9):688–698. 

3. G Wang et al. In vivo antitumor 

activity of interleukin 21 mediated by 

natural killer cells. Cancer Res. 2003 

Dec15;63(24):9016–9022. 

Patent Status: U.S. Patent Application 

No. 10/508,978 filed 19 Nov 2004 (HHS 

Reference No. E–137–2002/0–US–03). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Jennifer Wong; 

301–435–4633; wongje@mail.nih.gov. 

Dated: July 1, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–16300 Filed 7–8–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

qPCR Assay for Detection of JC Virus 

Description of Invention: JC Virus 

causes a fatal disease in the brain called 

progressive multifocal 

leukoencephalopathy (PML) that occurs 

in many patients with 

immunocompromised conditions. For 

example, more than five percent (5%) of 

AIDS patients develop PML. 

Additionally, these conditions include, 

but are not limited to, cancers such as 

leukemias and lymphomas, organ 

transplants such as kidney, heart and 

autoimmune conditions with treatment 

that modulates the immune system such 

as Multiple Sclerosis (MS), rheumatoid 

arthritis, psoriasis, and systemic lupus 

erythematosus. The finding of JCV DNA 

in the patients with neurological 

symptoms of PML is a diagnostic 

criterion and is needed to confirm the 

diagnosis of PML to rule out other 

neurological conditions. 

This technology describes a qPCR 

assay that utilizes viral DNA standards 

and testing samples to detect the 

presence of the JC viral genome in 

patients’ cerebrospinal fluid and blood, 

blood products, and tissue samples from 

biopsy or autopsy. 

Application: Development of JC Virus 

(JCV) diagnostics, calibration of existing 

JCV assays. 

Advantages: Assay is sensitive, 

reproducible and highly specific 

because the amount of JCV DNA in 

cerebrospinal fluid or blood or blood 

product samples may be very small. 

Development Status: Materials and 

assay have been developed and tested. 

Inventors: Eugene O. Major and 

Caroline Ryschkewitsch (NINDS). 

Publications 

1. ML Landry et al. False negative 

PCR despite high levels of JC virus DNA 

in spinal fluid: Implications for 

diagnostic testing. J Clin Virol. 2008 

Oct;43(2):247–249. 

2. C Ryschkewitsch et al. Comparison 

of PCR-southern hybridization and 

quantitative real-time PCR for the 

detection of JC and BK viral nucleotide 

sequences in urine and cerebrospinal 

fluid. J Virol Methods. 2004 

Nov;121(2):217–221. 

3. T Yousry et al. Evaluation of 

patients treated with natalizumab for 

progressive multifocal 

leukoencephalopathy. N Engl J Med. 

2006 Mar 2;354(9):924–933. 

Patent Status: HHS Reference No. E– 

152–2009/0—Research Material. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301–435–4646; 

soukasp@mail.nih.gov. 

A Locking Device for Permanently 

Securing Surgical Suture Loops 

Description of Invention: This 

technology relates to a device that can 

be used to non-invasively secure 

surgical suture loops when combined 

with a percutaneous delivery system. It 

has been shown to be effective in 

correcting mitral valve regurgitation 

(MVR) in an animal model. During the 

procedure, a guidewire is 

percutaneously conveyed to the atrium 

of the heart and is used to secure the 

‘‘cerclage’’ suture encircling the mitral 

valve annulus, which is delivered using 

a delivery catheter. The locking device 

is advanced over the suture by the 

delivery catheter and it permanently 

secures the suture and maintains the 

tension on the annulus once the 

delivery system is removed. This 

locking device, in combination with the 

percutaneous procedure, allows for 

more complete coaptation of the valve 

leaflets and correction of MVR without 

the need for open heart surgery and its 

associated risks. The locking device is 

also adjustable, allowing the user to 

vary the tension on the suture if further 

tightening or loosening is required. It is 

also MRI compatible and all follow-up 

studies can be performed under MRI. 

This invention has demonstrated its 

ability to correct MVR in animals where 

the locking device was observed to 

maintain the correct position and 

tension after implantation. This device 

has the potential to replace the 

traditional loop and knot method used 

for surgical correction of MVR, and may 

also be useful for other conditions that 

require permanently secured suture 

loops. 

Applications: Non-invasive and 

effective correction of MVR and other 

conditions; Tensioning device for 

securing suture loops. 

Advantages: Technology amenable to 

a non-invasive technique; Control of 

tension on surgical sutures. 

Development Status: Early stage. 

Inventor: Ozgur Kocaturk (NHLBI). 

Patent Status: U.S. Provisional 

Application No. 61/157,267 filed 04 Mar 

2009 (HHS Reference No. E–048–2009/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Jeffrey A. James, 

Ph.D.; 301–435–5474; 

jeffreyja@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Heart, Lung and Blood 

Institute Cardiac Catheterization Lab is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize the 


rmajette on DSK29S0YB1 with NOTICES
Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 32941 

tension fixation device. Please contact 

Peg Koelble at 301–594–4095 or 

koelblep@nhlbi.nih.gov for more 

information. 

Modulators of Pregnane X Receptor 

(PXR) as Therapeutics for Bowel 

Disorders (BD) 

Description of Invention: This 

technology is based on the novel 

findings that susceptibility to BD is 

strongly associated with genetic 

variation in the PXR gene, a member of 

the nuclear receptor family, and 

rifaximin is a specific activator of 

human PXR. PXR is an integral 

component of the body’s defense 

mechanism involved in endogenous and 

xenobiotic detoxication. Based on these 

novel findings, the present technology 

provides (a) methods of screening for 

compositions that modulate 

inflammatory bowel disease (IBD), (b) 

methods of inhibiting inflammation of 

the bowel and related tissues and 

organs, and (c) methods of treatment of 

inflammatory bowel disease. 

Applications: Therapeutics for bowel 

disorders; Screening assays for 

candidate drugs to treat bowel 

disorders. 

Development Status: Early stage. 

Market: It is estimated that as many as 

one (1) million Americans have IBD, 

with that number evenly split between 

Crohn’s disease and Ulcerative Colitis 

(UC). Further, it is estimated that the 

IBD therapeutic market will grow to 

reach four (4) billion U.S. dollars in 

2017. 

Inventors: Frank J. Gonzalez (NCI), 

Xiaochao Ma (NCI), et al. 

Publication: X Ma, Y Shah, C Cheung, 

GL Guo, L Feigenbaum, KW Krausz, JR 

Idle, FJ Gonzalez. The PREGnane X 

receptor gene-humanized mouse: a 

model for investigating drug-drug 

interactions mediated by cytochromes 

P450 3A. Drug Metab Dispos. 2007 

Feb;35(2):194–200. 

Patent Status: U.S. Provisional 

Application No. 60/999,234 filed 17 Oct 

2007 (HHS Reference No. E–002–2008/ 

0–US–01); PCT Patent Application 

(HHS Reference No. E–002–2008/0– 

PCT–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Suryanarayana 

(Sury) Vepa, PhD, J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Metabolism, Center 

for Cancer Research, NCI, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize compounds that 

ameliorate bowel disorders through the 

PXR pathway. Please contact Lisa 

Finkelstein, PhD at 301–451–7458 or 

lfinkels@mail.nih.gov for more 

information. 

The Protein Cyanovirin Inactivates HIV 

and Influenza 

Description of Invention: CyanovirinN (CV–N) potently and irreversibly 

inactivates diverse primary strains of 

HIV–1, including M-tropic forms 

involved in sexual transmission of HIV, 

as well as T-tropic and dual-tropic 

forms. CV–N also blocks cell-to-cell 

transmission of HIV infection. CV–N 

interacts in an unusual manner with the 

viral envelope, binding with extremely 

high affinity to poorly immunogenic 

epitopes on gp120. Further, CV–N and 

homologous proteins and peptides 

potently inhibit diverse isolates of 

influenza viruses A and B, the two 

major types of influenza virus that infect 

humans. 

The described technology includes 

glycosylation-resistant mutants, which 

code sequences to enable ultra largescale recombinant production of 

functional CV–Ns in non-bacterial (yeast 

or insect) host cells or in transgenic 

animals or plants. Therefore, these 

glycosylation-resistant mutants may 

allow industry to produce CV–Ns on a 

large scale and make CV–Ns cheap 

enough for developing countries to 

benefit from this invention. 

CV–N was benign in vivo when tested 

in the rabbit/monkey vaginal toxicity/ 

irritancy model and was not cytotoxic in 

vitro against human immune cells and 

lactobacilli. CV–N is readily soluble in 

aqueous media, is remarkably resistant 

to physicochemical degradation and is 

amenable to very large-scale production 

by a variety of genetic engineering 

approaches. 

Applications 

• Therapeutics and prevention of HIV 

and influenza infections. 

• Topical microbicide to protect HIV 

infection. 

• Ex vivo devices incorporating CV– 

N to remove or inactivate HIV from fluid 

samples. 

Advantages 

• Potent anti-HIV and anti-influenza 

activity. 

• Can be applied both systematically 

or locally. 

• Can be applied both in vivo and ex 

vivo. 

• Inexpensive and large scale 

manufacturing. 

Development Status 

• Preclinical (rabbit/monkey) data in 

microbicide field are available at this 

time. 

• Initial animal efficacy studies (both 

mouse and ferret) against influenza 

(H1N1) have been completed and 

published. 

Market: For HIV therapeutics market, 

a published report by the financial 

services firm Griffin Securities 

suggested that sales of HIV/AIDS drugs 

reached $13 billion annually in 2007 

(http://www.hivandhepatitis.com). 

For microbicide market, it has been 

estimated that the global market size of 

microbicide will reach to $900 million 

by 2011 and will reach the sales of over 

$1.8 billion by 2020). ‘‘Promising 

microbicides’’ Frontline (Volume 21— 

Issue 14, Jul. 03–16, 2004). 

For influenza market, based on Report 

Buyer which is a UK-based independent 

online store supplying business 

information on major industry sectors: 

By 2010, the worldwide influenza 

market is likely to reach $7.1 billion, 

with average annual growth estimated at 

19.8%. 

Inventors: Michael R. Boyd (NCI), 

Barry R. O’Keefe (NCI), et al. 

Publications 

1. B Giomarelli, R Provvedi, F Meacci, 

T Maggi, D Medaglini, G Pozzi, T Mori, 

JB McMahon, R Gardella, MR Boyd. The 

microbicide cyanovirin-N expressed on 

the surface of commensal bacterium 

Streptococcus gordonii captures HIV–1. 

AIDS. 2002 Jul 5;16(10):1351–1356. 

2. CC Tsai, P Emau, Y Jiang, MB Agy, 

RJ Shattock, A Schmidt, WR Morton, KR 

Gustafson, MR Boyd. Cyanovirin-N 

inhibits AIDS virus infections in vaginal 

transmission models. AIDS Res Hum 

Retroviruses. 2004 Jan; 20(1):11–18. 

3. DF Smee, KW Bailey, MH Wong, 

BR O’Keefe, KR Gustafson, VP Mishin, 

LV Gubareva. Treatment of influenza A 

(H1N1) virus infections in mice and 

ferrets with cyanovirin-N. Antiviral Res. 

2008 Dec;80(3):266–271. 

Patent Status 

• E–117–1995/0—US Patent Numbers 

5,843,882; 6,015,876; 5,962,653; 

6,245,737 and 6,586,392. 

• E–117–1995/1—US Patent Numbers 

5,821,081; 5,998,587; 6,987,096; and 

5,962,668. 

• E–117–1995/2–PCT–01 (WO 96/ 

34107)—entered in AU with Patent 

Numbers 707781 and 746809; in CA 

with Patent application Numbers 

2219105; in JP with Patent Numbers 

3803115 and 4081484; and in EP with 

Patent Number 836647 and registration 

GB, FR, DE, BE and CH. 

• E–117–1995/3–PCT–02 (WO 00/ 

11036)—entered in USA with Patent 

Number 6,193,982; in AU with Patent 

Number 746313; in CA with Patent 

Application Number 2340787; in JP 


rmajette on DSK29S0YB1 with NOTICES
32942 Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 

with Patent Application Number 

566308/2000; and in EP with Patent 

Application Number 99943784.1. 

• E–074–1999/0—US Patent Numbers 

6,420,336 and 6,743,577. 

• E–074–1999/1—US Patent Numbers 

7,105,169; 7,048,935; and 6,428,790. 

• E–074–1999/2–PCT–01 (WO 00/ 

53213)—entered in AU with Patent 

Numbers 762704 and 2003252207; in 

CA with Patent Application Numbers 

2364500; in JP with Patent Application 

Number 603702/2000; and in EP with 

Patent Number 1162992 and registration 

GB, FR, DE, BE and CH. 

• E–074–1999/3–PCT–02 (WO 02/ 

077189)—entered in USA with Patent 

Numbers 7,339,037 & 6,780,847 and 

Patent Application Number 10/857,265; 

in AU with Patent Number 2002254382; 

in CA with Patent Application Number 

2441287; in JP with Patent Application 

Number 576632/2002; and in EP with 

Patent Number 1456382 and registration 

GB, FR, DE, BE and CH. 

• E–198–2006/0–PCT–02 (WO 2008/ 

022303)—entered in USA with Patent 

Application Number 12/377875; and in 

EP with Patent Application Number 

07814209.8. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sally Hu, PhD, 

301–435–5606, HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, 

Molecular Targets Development 

Program, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact John D. Hewes, PhD at 301–435– 

3121 or hewesj@mail.nih.gov for more 

information. 

Novel Osteobiologic Proteins for 

Treatment of Osteoporosis, Rheumatoid 

and Neurologic Diseases 

Description of Invention: In an effort 

to find effective strategies for treatment 

of body tissue and structural damage as 

the result of trauma, cancer and other 

diseases, scientists at the National 

Institutes of Health (NIH) and the Food 

and Drug Administration (FDA) have 

identified proteins and associated 

pathways instrumental in replacing or 

regenerating damaged tissue. The 

identified proteins include CartilageDerived Morphogenetic Proteins 

(CDMP), Bone Morphogenetic Proteins 

(BMPs) and a tissue fate modifying 

FRZB Protein. Each has unique 

activities likely to be useful as stand 

alone agents or in construction of 

engineered tissues. 

CDMPs appear helpful in the healing 

of bone and joint surface lesions, and 

also for the repair or reconstruction of 

cartilaginous tissues, tendons and 

ligaments. BMP antagonists will be 

useful in the study of stem cell 

differentiation. FRZB Protein, a tissue 

fate modifying secretable antagonist of 

Wnt signaling, is involved in the 

formation of cartilage, bone, neural and 

muscle tissue. 

Potential Areas of Application 

• Rheumatic diseases of the bone. 

• Osteoporosis and osteoarthritis. 

• Wound healing. 

• Neurodegenerative disorders. 

• Growth and repair of 

musculoskeletal tissues. 

• Tissue engineering. 

Cartilage-Derived Morphogenetic 

Proteins (HHS Reference No. E–138– 

1994/0) 

• Useful in the therapeutic induction, 

repair, and maintenance of skeletal 

tissues and cartilage growth. 

• Polynucleotides encoding these 

proteins are effective diagnostic reagents 

for detecting genetic abnormalities 

associated with poor skeletal 

development. 

Tissue Fate Modifying FRZB Protein 

(HHS Reference Nos. E–127–1995/0/1/2) 

• Involved in the formation of 

cartilage, bone, neural and muscle 

tissue. 

• Regenerative agent to treat 

degenerative disorders (i.e., 

Huntington’s, Alzheimer’s or spinal 

cord injuries), myodegenerative 

disorders (i.e., muscular dystrophy, 

myasthenia gravis or myotonic 

myopathies) and osteodegenerative 

disorders (i.e., osteoporosis or 

osteoarthritis) 

• Selectively blocks diseases 

associated with Wnt family of signaling 

molecules including neoplasias. 

Bone Morphogenetic Protein Variants 

(HHS Reference No. E–196–2004/0) 

• Promote repair of menisci, cruciate 

and collateral ligaments of the knee, and 

rotator cuff or other tendons and/or 

ligaments. 

• Induce the proliferation and 

differentiation of progenitor cells into 

functional bone, cartilage, tendon, or 

ligament tissue. 

Advantages: Osteobiologics, such as 

BMPs, have the ability to stimulate 

musculo-skeletal repair instead of using 

donated human tissue allografts and 

synthetic materials. 

Market Size: Ankylosing spondylitis 

afflicts least half a million people in the 

United States. Currently, there remains 

a need for the development of effective 

therapeutics for treating 

spondyloarthropathies that could 

overcome the disadvantages of current 

drugs. 

Osteoarthritis overall affects an 

estimated 30 million US adults. Direct 

medical expenses for arthritis and other 

rheumatic conditions are estimated at 

$80.8 billion. In the United States, 10 

million people have Osteoporosis. 

Osteoporosis related fractures attributed 

for $21 billion with the number 

expected to rise to $26 billion in 2025. 

Inventors: Malcolm C. Moos Jr. (FDA), 

Frank P. Luyten (NIDCR), et al. 

Related Publications 

1. K Lin, S Wang, MA Julius, J 

Kitajewski, M Moos Jr., FP Luyten. The 

cysteine-rich frizzled domain of Frzb-1 

is required and sufficient for the 

modulation of Wnt signaling. Proc Natl 

Acad Sci. USA 1997 Oct 

14;94(21):11196–11200. 

2. B Hoang, M Moos Jr, S Vukicevic, 

FP Luyten. Primary structure and tissue 

distribution of FRZB, a novel protein 

related to Drosophila frizzled, suggests a 

role in skeletal morphogenesis. J Biol 

Chem. 1996 Oct 18;271(42):26131– 

26137. 

Patent Status 

Cartilage-Derived Morphogenetic 

Proteins (HHS Reference No. E–138– 

1994/0) 

• U.S. Patent 7,148,036 issued 12 Dec 

2006. 

• U.S. Patent 7,220,558 issued 22 

May 2007. 

• U.S. Patent Application No. 11/ 

592,811 (allowed). 

Tissue Growth-Inducing FRZB Protein 

(HHS Reference Nos. E–127–1995/0/1/2) 

• U.S. Patent 6,884,871 issued 26 Apr 

2005. 

• U.S. Patent 6,924,367 issued 02 Aug 

2005. 

• U.S. Patent 7,049,291 issued 23 

May 2006. 

• U.S. Patent Application No. 11/ 

184,005 (allowed). 

• U.S. Patent Application No. 11/ 

369,089 (pending). 

Bone Morphogenetic Variants (HHS 

Reference No. E–196–2004/0) 

• U.S. Patent Application No. 11/ 

916,990 (pending). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Surekha Vathyam, 

PhD; 301–435–4076; 

vathyams@mail.nih.gov. 


rmajette on DSK29S0YB1 with NOTICES
Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 32943 

Dated: June 30, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–16299 Filed 7–8–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; Time 

Sensitive Applications. 

Date: July 16, 2009. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Aileen Schulte, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd, Room 6140, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–1225, 

aschulte@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: July 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–16214 Filed 7–8–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, IBD Genetics 

Ancillary Studies. 

Date: July 29, 2009. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Dan E. Matsumoto, Ph.D., 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 749, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–8894, matsumotod@extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: July 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–16092 Filed 7–8–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Subcommittee on Procedures 

Reviews, Advisory Board on Radiation 

and Worker Health (ABRWH), National 

Institute for Occupational Safety and 

Health (NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting for the 

aforementioned subcommittee: 

Time and Date: 10 a.m.–5 p.m., August 13, 

2009. 

Place: Cincinnati Airport Marriott, 2395 

Progress Drive, Hebron, Kentucky 41018. 

Telephone (859) 334–4611, Fax (859) 334– 

4619. 

Status: Open to the public, but without a 

public comment period. To access by 

teleconference dial the following information 

1(866)659–0537, Participant Pass Code 

9933701. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation Program 

Act of 2000 to advise the President on a 

variety of policy and technical functions 

required to implement and effectively 

manage the compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines that have 

been promulgated by the Department of 

Health and Human Services (HHS) as a final 

rule; advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule; advice 

on the scientific validity and quality of dose 

estimation and reconstruction efforts being 

performed for purposes of the compensation 

program; and advice on petitions to add 

classes of workers to the Special Exposure 

Cohort (SEC). 

In December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, which 

subsequently delegated this authority to CDC. 

NIOSH implements this responsibility for 

CDC. The charter was issued on August 3, 

2001, renewed at appropriate intervals, and 

will expire on August 3, 2009. 

Purpose: The Advisory Board is charged 

with (a) Providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) providing 

advice to the Secretary, HHS, on the 

scientific validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at any 

Department of Energy facility who were 

exposed to radiation but for whom it is not 

feasible to estimate their radiation dose, and 

on whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of this 

class. The Subcommittee on Procedures 


rmajette on DSK29S0YB1 with NOTICES